Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study.

Published in: Sao Paulo medical journal = Revista paulista de medicina (2020)

Reducing drug acquisition costs may improve access to EGFR-targeted therapy for lung cancer.

Keyphrases